Medical Condition News

RSS

The LINC complex essential for hearing

In this issue of the Journal of Clinical Investigation, Karen Avraham and colleagues at Tel Aviv University identified a genetic mutation in two families with hereditary high frequency hearing loss. The mutated gene, which has not previously been linked to hearing loss, encodes NESP4, a protein that is expressed in the outer nuclear membrane (ONM) of the hair cells of the ear.

28 Jan 2013

Immunosuppressive drugs do not increase risk of cancer in lupus patients

People who take immunosuppressive drugs to treat lupus do not necessarily increase their cancer risk according to new research led by scientists at the Research Institute of the McGill University Health Centre (RI-MUHC).

28 Jan 2013

Neuroscientists develop new way to stop epileptic seizures with fiber-optic light signals

UC Irvine neuroscientists have developed a way to stop epileptic seizures with fiber-optic light signals, heralding a novel opportunity to treat the most severe manifestations of the brain disorder.

28 Jan 2013

Dairy cows that are fed flaxseed produce more nutritious milk

Dairy cows that are fed flaxseed produce more nutritious milk, according to a new study by Oregon State University.

28 Jan 2013

Study sheds new light on learning and memory-making

In experiments on rats outfitted with tiny goggles, scientists say they have learned that the brain's initial vision processing center not only relays visual stimuli, but also can "learn" time intervals and create specifically timed expectations of future rewards.

28 Jan 2013

LOX enzyme can create scarred microenvironment that enhances cancer spreading

What to fear most if faced by a cancer diagnosis is the spread of the cancer to other parts of the body. This process called metastasis accounts for over 90% of cancer patient deaths and therefore is a strong focus for cancer researchers.

28 Jan 2013

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced the initiation of a global phase III clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed CD30-positive mature T-cell lymphoma (MTCL) patients, including patients with systemic anaplastic large cell lymphoma (sALCL) and other types of peripheral T-cell lymphomas.

28 Jan 2013

Study explores regular aspirin use and potential risks for macular degeneration

This week, a study published in the journal JAMA Internal Medicine, explored the connection between regular aspirin use and the potential risks for developing the blinding eye disease, macular degeneration. As a result, there is increased confusion and anxiety in the general public about whether aspirin can harm your vision and what to do if you need the heart-protective therapy.

28 Jan 2013

Alzheimer's Association, SNMMI publish appropriate use criteria for brain amyloid imaging with PET

Only recently has it become possible to create high-quality images of the brain plaques characteristic of Alzheimer's disease in living people through positron emission tomography (PET). Even so, questions remain about what can be learned from these PET images and which people should have this test.

28 Jan 2013

Sanofi Canada announces new option for emergency treatment of anaphylaxis

Sanofi Canada announces a new option for the emergency treatment of anaphylaxis. Allerject is the first and only 'talking' epinephrine auto-injector in Canada.

28 Jan 2013

HSS involving resiniferatoxin receives U.S. patent to alleviate intractable pain

The U. S. Patent and Trademark Office recently issued a patent to the U. S. Department of Health and Human Services involving resiniferatoxin, or RTX, an experimental compound that represents a potential new class of drugs to alleviate the intractable pain that can occur in people with advanced cancer, severe arthritis, and other extremely chronic conditions.

28 Jan 2013

UMDNJ-School of Osteopathic Medicine to develop blood test that can diagnose MCI

The Biomarker Discovery Center at the University of Medicine and Dentistry of New Jersey-School of Osteopathic Medicine has been awarded a three-year, $799,800 grant from the Osteopathic Heritage Foundation to develop a blood test that can diagnose mild cognitive impairment (MCI) caused by early-stage Alzheimer's disease.

28 Jan 2013

Positive top-line results from Biogen Idec’s peginterferon beta-1a Phase 3 trial on RRMS

Today Biogen Idec released the primary efficacy analysis and safety data from its Phase 3 pivotal clinical trial, ADVANCE.

28 Jan 2013

FDA accepts Genzyme’s LEMTRADA sBLA for review

Genzyme, a Sanofi Company, announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's supplemental Biologics License Application (sBLA) file seeking approval of LEMTRADA (alemtuzumab) for the treatment of relapsing multiple sclerosis (RMS).

28 Jan 2013

Study sheds new light on why certain people are more likely to suffer from RA

University of Michigan research sheds new light on why certain people are more likely to suffer from rheumatoid arthritis - paving the way to explore new treatments for both arthritis and other autoimmune diseases.

28 Jan 2013

AstraZeneca, Orexo partner on OX-CLI preclinical program to treat respiratory diseases

Orexo AB announced today that the company has entered into an agreement with AstraZeneca regarding OX-CLI, a preclinical program for a potential novel treatment of respiratory diseases.

28 Jan 2013

TSRI scientists to identify, test and develop drug candidates for several neurodegenerative disorders

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded approximately $1.2 million from the U.S. National Institute of General Medical Sciences of the National Institutes of Health to identify, test and develop a series of drug candidates for a number of diseases, including rheumatoid arthritis, heart disease and several neurodegenerative disorders.

28 Jan 2013

IRHOM2-targeted drugs can effectively treat patients with rheumatoid arthritis

Researchers at Hospital for Special Surgery have identified a potential new target for drugs to treat patients with rheumatoid arthritis (RA), a protein known as IRHOM2. The finding could provide an effective and potentially less toxic alternative therapy to tumor necrosis factor-alpha blockers (TNF-blockers), the mainstay of treatment for rheumatoid arthritis, and could help patients who do not respond to this treatment. Efforts to develop drugs that hone in on this new target are underway.

28 Jan 2013

New AngioSculpt catheters from AngioScore can treat peripheral artery disease below the knee

AngioScore, Inc., a developer of novel angioplasty catheters for use in the treatment of cardiovascular disease, today announced the launch of its new 100 mm length AngioSculpt PTA Scoring Balloon Catheters for the treatment of peripheral artery disease (PAD) below the knee (BTK).

28 Jan 2013

FDA approves Takeda’s NESINA, OSENI and KAZANO for treatment of type 2 diabetes

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.

28 Jan 2013

Medical Condition News

The LINC complex essential for hearing

Immunosuppressive drugs do not increase risk of cancer in lupus patients

Neuroscientists develop new way to stop epileptic seizures with fiber-optic light signals

Dairy cows that are fed flaxseed produce more nutritious milk

Study sheds new light on learning and memory-making

LOX enzyme can create scarred microenvironment that enhances cancer spreading

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

Study explores regular aspirin use and potential risks for macular degeneration

Alzheimer's Association, SNMMI publish appropriate use criteria for brain amyloid imaging with PET

Sanofi Canada announces new option for emergency treatment of anaphylaxis

HSS involving resiniferatoxin receives U.S. patent to alleviate intractable pain

UMDNJ-School of Osteopathic Medicine to develop blood test that can diagnose MCI

Positive top-line results from Biogen Idec’s peginterferon beta-1a Phase 3 trial on RRMS

FDA accepts Genzyme’s LEMTRADA sBLA for review

Study sheds new light on why certain people are more likely to suffer from RA

AstraZeneca, Orexo partner on OX-CLI preclinical program to treat respiratory diseases

TSRI scientists to identify, test and develop drug candidates for several neurodegenerative disorders

IRHOM2-targeted drugs can effectively treat patients with rheumatoid arthritis

New AngioSculpt catheters from AngioScore can treat peripheral artery disease below the knee

FDA approves Takeda’s NESINA, OSENI and KAZANO for treatment of type 2 diabetes

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Latest News